The estimated Net Worth of Plcastrazeneca Ab Astrazeneca is at least $49.4 Millón dollars as of 28 September 2018. Plcastrazeneca Astrazeneca owns over 246,666 units of Entasis Therapeutics Inc stock worth over $4,741,032 and over the last 10 years Plcastrazeneca sold ETTX stock worth over $44,700,000.
Plcastrazeneca has made over 3 trades of the Entasis Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Plcastrazeneca bought 246,666 units of ETTX stock worth $3,699,990 on 28 September 2018.
The largest trade Plcastrazeneca's ever made was selling 2,000,000 units of Entasis Therapeutics Inc stock on 12 November 2014 worth over $34,000,000. On average, Plcastrazeneca trades about 915,555 units every 472 days since 2014. As of 28 September 2018 Plcastrazeneca still owns at least 2,164,855 units of Entasis Therapeutics Inc stock.
You can see the complete history of Plcastrazeneca Astrazeneca stock trades at the bottom of the page.
Plcastrazeneca's mailing address filed with the SEC is 2 KINGDOM STREET85, , LONDONSODERTALJE, X0V7, W2 6BDSE-151.
Over the last 6 years, insiders at Entasis Therapeutics Inc have traded over $348,925 worth of Entasis Therapeutics Inc stock and bought 50,891,639 units worth $170,673,776 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Inc.Innoviva Strategic Oppo... y Holdings A/S Novo. On average, Entasis Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $4,855,580. The most recent stock trade was executed by Inc.Innoviva Strategic Oppo... on 8 July 2022, trading 19,270,476 units of ETTX stock currently worth $42,395,047.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).
Entasis Therapeutics Inc executives and other stock owners filed with the SEC include: